Long-Term Safety Study of Bicifadine for the Treatment of Chronic Low Back Pain
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00281645|
Recruitment Status : Completed
First Posted : January 25, 2006
Last Update Posted : March 27, 2007
The primary objective of the study is to evaluate the safety and efficacy of bicifadine 400 mg BID for up to one year in patients with moderate to severe chronic low back pain.
The secondary objectives are to compare the long-term safety of bicifadine to standard of care therapy, to evaluate the safety of bicifadine following discontinuation of dosing, and to evaluate the safety and efficacy of lower doses of bicifadine in patients who do not tolerate bicifadine 400 mg BID.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Low Back Pain||Drug: Bicifadine Drug: Standard of Care (pharmacological analgesic treatment)||Phase 3|
There are two ways by which subjects could enter this study.
Subjects who completed 12 weeks of treatment in two other double blind clinical studies of bicifadine (Studies 020 and 021, both in the United States) could roll over into this study.
Also, de novo subjects (that is, subjects who had not previously received bicifadine) could enroll in this study.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||1250 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter Standard of Care-Controlled Study to Evaluate the Long-Term Safety of Bicifadine for the Treatment of Chronic Low Back Pain|
|Study Start Date :||December 2004|
- Adverse Events
- Clinical Labs
- Vital Signs
- Pain Severity Rating (VAS)
- Short-Form McGill Pain Questionnaire (SF-MPQ)
- Roland-Morris Disability Questionnaire (RDQ)
- Short-Form 36 (SF-36) Health Survey
- Patient Withdrawal Checklist